Details of the Drug

General Information of Drug (ID: DM7LIV2)

Drug Name
REGN3051
Indication
Disease Entry ICD 11 Status REF
Coronavirus infection 1D92 Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D9U5LY
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
COVID-19 spike glycoprotein (S) TTZ3COY SPIKE_SARS2 Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03301090) A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051. U.S. National Institutes of Health.
2 Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res. 2018 Aug;156:64-71.